Very interesting stuff thats not helping share price
PBIO needs to get their financial house, among other things, in order to be taken seriously. This will be an interesting Q coming up. Hope the CEO can explain the plans in place to fund PBIO and this years planned up listing which Im sure is not going to happen.
Big salaries being paid and trips all over the place for these useless equity conferences doesnt seem the best use of funds.
Instead why not hire the sales people they keep promising to do??
Very important 10Q. Hopefully showing sales traction with Sciex and organically or this stock may push even lower
Ground Breaking Life Sciences Company Pursues $6 Billion Market
In this episode of CEOLIVE.TV we have an in-depth conversation with Mr. Richard Schumacher, CEO of Pressure BioScience (PBIO).
Pressure Bio develops, markets and sells proprietary lab instruments and consumables to the $6 billion life science sample prep market.
Their patented PCT platform has been installed in over 250 PCT systems in 160 sites worldwide.
The company’s PCT product line has grown rapidly over the past year and as a result, product revenue has jumped 8.3% and total revenue increased 34% last year.
Although it’s in the early stages of commercialization the company’s PCT platform holds competitive advantages over incumbent technologies in many important aspects related to sample preparation.
A report from Zach’s Small Cap Research Analyst, Grant Zeng, stated that PBIO’s shares are deeply undervalued and based on current fundamentals gave a conservative price target of $2.50 per share.
Pressure Bio was also recently featured in an article on SECFilings.com, “How to Invest in the Cancer Moonshot” which you can read here: http://bit.ly/2f5JbDA
Company Overview
Pressure BioSciences, Inc. (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company’s products are based on the unique properties of both constant and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. The Company’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Valuation
PBIO’s Pressure Cycling Technology platform (PCT) is patented and uses alternate cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant and microbial sources. The Company has sold 300 instrument systems worldwide to leading academic, government, biotech and pharma laboratories. Additionally, there have been over 100 journal articles and peer reviewed publications on the advantages of PCT technology. Following a recent $6.3 million capital raise, a recent co-marketing deal with SCIEX (leader in mass spectrometry (MS)), and an expansion of the Company’s sales and marketing team, sales should begin to show strong increases going forward.
PBIO CEO Richard T. Schumacher is a serial entrepreneur who has had substantial success in growing and operating Biotech and Pharma businesses in the past; as President and Co-founder of Panacos Pharma, he helped to significantly improve the Company from a struggling start-up to a $700 million market cap in five years. Relative to sales potential, if PBIO can capture only 25% of the market opportunity in MS, it could lead to $75 million in device sales and $36 million in annual, recurring revenue. Additional long-term opportunities for PCT also exist.
News 
Market Data 
Discover 
